The Relationship between High Flow Nasal Cannula Flow Rate and Effort of Breathing in Children - 23/09/17
, Asavari Kamerkar, DO 1, 2, Justin Hotz, RRT 1, Patrick A. Ross, MD 1, 2, Christopher J.L. Newth, MD, FRCPC 1, 2, Robinder G. Khemani, MD, MsCI 1, 2Abstract |
Objective |
To use an objective metric of effort of breathing to determine optimal high flow nasal cannula (HFNC) flow rates in children <3 years of age.
Study design |
Single-center prospective trial in a 24-bed pediatric intensive care unit of children <3 years of age on HFNC. We measured the percent change in pressure∙rate product (PRP) (an objective measure of effort of breathing) as a function of weight-indexed flow rates of 0.5, 1.0, 1.5, and 2.0 L/kg/minute. For a subgroup of patients, 2 different HFNC delivery systems (Fisher & Paykel [Auckland, New Zealand] and Vapotherm [Exeter, New Hampshire]) were compared.
Results |
Twenty-one patients (49 titration episodes) were studied. The most common diagnoses were bronchiolitis and pneumonia. Overall, there was a significant difference in the percent change in PRP from baseline (of 0.5 L/kg/minute) with increasing flow rates for the entire cohort (P < .001) with largest change at 2.0 L/kg/min (−21%). Subgroup analyses showed no significant difference in percent change in PRP from baseline when comparing the 2 different HFNC delivery systems (P = .12). Patients ≤8 kg experienced a larger percent change in PRP as HFNC flow rates were increased (P = .001) than patients >8 kg.
Conclusions |
The optimal HFNC flow rate to reduce effort of breathing in infants and young children is approximately 1.5-2.0 L/kg/minute with more benefit seen in children ≤8 kg.
Le texte complet de cet article est disponible en PDF.Keywords : effort of breathing, pressure ⋅ rate product, high flow nasal cannula
Abbreviations : CHLA, FP, HFNC, IBW, PA, PRP, RIP, VT
Plan
| Vapotherm, Inc. provided a limited number of high flow nasal cannula delivery systems for use in this study but this company did not have any role in (1) study design, (2) collection, analysis, and interpretation of data, (3) the writing of the report, or (4) the decision to submit the paper for publication. The authors declare no conflicts of interest. |
Vol 189
P. 66 - octobre 2017 Retour au numéro
Article précédent
- Safety and Efficacy of Warfarin Therapy in Kawasaki Disease
- Annette L. Baker, Christina Vanderpluym, Kimberly A. Gauvreau, David R. Fulton, Sarah D. de Ferranti, Kevin G. Friedman, Jenna M. Murray, Loren D. Brown, Christopher S. Almond, Margaret Evans-Langhorst, Jane W. Newburger
- Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome
- Francesca Minoia, Francesca Bovis, Sergio Davì, Antonella Insalaco, Kai Lehmberg, Susan Shenoi, Sheila Weitzman, Graciela Espada, Yi-Jin Gao, Jordi Anton, Toshiyuki Kitoh, Ozgur Kasapcopur, Helga Sanner, Rosa Merino, Itziar Astigarraga, Maria Alessio, Michael Jeng, Vyacheslav Chasnyk, Kim E. Nichols, Zeng Huasong, Caifeng Li, Concetta Micalizzi, Nicolino Ruperto, Alberto Martini, Randy Q. Cron, Angelo Ravelli, AnnaCarin Horne
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?